2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 616

Risk Factors for the Exacerbation of Interstitial Lung Disease (ILD) after Administration of Biologic Dmards in RA Patients with Pre-Existing ILD

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 32

Risk for Lung Cancer in RA and Different RA Phenotypes: Results from a Population-Based Case-Control Study

Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 31

Risk of Chronic Obstructive Pulmonary Disease in Rheumatoid Arthritis: A Population Based Cohort Study

Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 610

Risk of Herpes Zoster in Patients with Rheumatoid Arthritis Treated with Biologic Disease-Modifying Therapy Compared with Conventional Therapy

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 886

Rituximab As a Cyclophosphimide Sparing Agent for Patients with Multi-Relapsing Antineutrophil Cytoplasmic Antibody Associated Small Vessel Vasculitis

Vasculitis Poster I

9:00AM-11:00AM: Abstract Number: 567

Rituximab Associated Late Onset Neutropenia – a Rheumatology Case Series and Review of the Literature

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 277

Rituximab in Refractory Mixed Connective Tissue Disease: An Observational Study

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 751

Rituximab Induced Serum Sickness: A Systematic Review

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 615

Rituximab Non Responders Fail to Down Regulated CD19 on Naive B Cells

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 20

Role of the Epigenetic Regulator EZH2 in Proinflammatory Macrophage Polarization and Signaling in Rheumatoid Arthritis

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I

9:00AM-11:00AM: Abstract Number: 591

Rosuvastatin Improves Endothelial Function in Patients with Inflammatory Joint Diseases, Longitudinal Associations with Atherosclerosis and Arteriosclerosis

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 657

Routine Assessment of Patient Index Data 3 Score (RAPID3) and Psoriasis Quality of Life (PQoL-12) Assess Different Domains in Psoriasis (PsO) and Psoriatic Arthritis (PsA) Patients

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

9:00AM-11:00AM: Abstract Number: 685

Sacroiliitis Misdiagnosed As Spondyloarthritis: Clinical Analysis of 581 Cases

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

9:00AM-11:00AM: Abstract Number: 833

Safety and Immunogenicity of Pneumococcal Vaccine in Patients with Systemic Sclerosis and Healthy Controls

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster I

9:00AM-11:00AM: Abstract Number: 347

Safety Observations with 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab during the Pivotal 3-Year Trial and Subjects Who Crossed over to Denosumab during the Extension

Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].